Xencor, Inc. (NASDAQ:XNCR) Scheduled to Post Earnings on Monday
Xencor, Inc. (NASDAQ:XNCR) is scheduled to post its quarterly earnings results after the market closes on Monday, July 31st. Analysts expect Xencor to post earnings of ($0.28) per share for the quarter.
Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.06. Xencor had a net margin of 18.19% and a return on equity of 5.98%. The company had revenue of $4.34 million for the quarter, compared to the consensus estimate of $8.15 million. On average, analysts expect Xencor to post $-1.22 EPS for the current fiscal year and $-1.42 EPS for the next fiscal year.
Xencor, Inc. (NASDAQ XNCR) opened at 23.78 on Monday. Xencor, Inc. has a 52 week low of $18.10 and a 52 week high of $29.38. The firm’s 50-day moving average price is $21.78 and its 200 day moving average price is $23.23. The company has a market capitalization of $1.11 billion, a PE ratio of 67.37 and a beta of 2.13.
In related news, major shareholder John S. Stafford III bought 1,500 shares of the company’s stock in a transaction on Friday, June 16th. The shares were acquired at an average cost of $19.67 per share, with a total value of $29,505.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder John S. Stafford III bought 6,000 shares of the company’s stock in a transaction on Wednesday, June 28th. The stock was bought at an average cost of $19.94 per share, for a total transaction of $119,640.00. The disclosure for this purchase can be found here. Insiders sold 46,238 shares of company stock worth $1,037,822 over the last three months. Corporate insiders own 4.03% of the company’s stock.
Several equities research analysts recently weighed in on XNCR shares. Zacks Investment Research cut Xencor from a “buy” rating to a “hold” rating in a research note on Saturday, April 29th. Wedbush reaffirmed an “outperform” rating and issued a $29.00 price target on shares of Xencor in a research note on Wednesday, May 10th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $28.67.
WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/24/xencor-inc-nasdaqxncr-scheduled-to-post-earnings-on-monday.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.